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Summary
Objectives:  BRAF  pV600E  mutation  is  the  most  common  oncogenic  event  and  the  most  speciﬁc
mutation for  papillary  thyroid  carcinoma  (PTC).  Many  studies  over  the  last  decade  have  shown  a
direct relationship  between  BRAF  mutation  and  aggressive  tumour  characteristics,  resulting  in
poor prognosis.  However,  several  recent  studies  have  suggested  that  BRAF  mutation  is  not  asso-
ciated with  poor  prognosis  of  PTC.  The  present  study  was  designed  to  evaluate  the  association
between BRAF  mutation  with  clinicopathological  factors  and  tumour  recurrence.
Material  and  methods:  In  this  retrospective  study,  BRAF  mutation  status  was  examined  by
direct sequencing  on  parafﬁn-embedded  tumour  specimens  from  46  patients  undergoing  surgery
for PTC  in  our  institution  from  1985  to  2000.  The  relationship  between  BRAF  mutation  and
gender, advanced  age,  extrathyroid  extension,  multifocal  tumour,  cervical  lymph  node  metas-
tasis, tumour  size  and  advanced  pT  stage  of  PTC  and  its  predictive  role  for  the  risk  of  tumour
recurrence  were  investigated  with  a  median  follow-up  of  10.1  (±  6.5)  years.
Results:  BRAF  mutation  was  detected  in  20  of  the  46  patients  (43.5%)  included  in  the  study.  No
statistically  signiﬁcant  correlation  was  demonstrated  between  the  presence  of  BRAF  mutation
and the  various  clinicopathological  factors  studied.  No  signiﬁcant  difference  in  tumour  recur-
rence rate  or  radioiodine  sensitivity  was  observed  between  the  two  subgroups:  mutant  BRAF
and wild-type  BRAF.
Conclusion:  Although  BRAF  mutation  appears  to  play  a  role  in  local  tumour  progression,  it  is
not a  risk  factor  for  poor  prognosis  or  tumour  recurrence  in  PTC.
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apillary  thyroid  carcinoma  (PTC)  is  the  most  common  malig-
ant  thyroid  tumour.  The  growing  incidence  of  PTC  observed
ver  recent  decades  has  been  attributed  to  increasingly  reli-
ble  and  early  clinical  and  ultrasound  detection  [1].
PTC  has  an  excellent  prognosis  with  10-year  overall  sur-
ival  rates  higher  than  90%  after  appropriate  treatment  [1].
owever,  20  to  30%  of  patients  develop  local  recurrence
r  distant  metastasis  and  1%  die  from  their  cancer.  Iden-
iﬁcation  of  this  high-risk  group  at  the  time  of  diagnosis
ould  allow  more  appropriate  management  and  follow-up
or  these  patients.
Among  the  various  oncogenic  events  identiﬁed  in  PTC,  a
igh  prevalence  of  activating  mutation  of  the  gene  coding
or  BRAF  protein  kinase  has  been  observed.  This  protein  is  a
owerful  inducer  of  the  MAP  kinase  signalling  pathway  and
lays  an  important  role  in  growth  regulation,  cell  division
nd  proliferation.  This  mutation  is  observed  in  29  to  83%  of
TC.  It  is  speciﬁc  to  PTC  and  anaplastic  carcinomas  derived
rom  PTC  [2].
The  speciﬁcity  of  this  mutation  and  its  easy  detection
ake  it  an  attractive  genetic  marker  for  the  management
f  PTC.  Several  studies  have  demonstrated  a  signiﬁcant
ssociation  between  BRAF  mutation  and  clinicopathological
actors  of  poor  prognosis,  although  this  association  remains
ontroversial.
The  present  study  was  designed  to  evaluate  the  progno-
tic  impact  of  BRAF  mutation  and  its  impact  on  radioiodine
esistance  in  PTC.
aterial and methods
atients
eventy  patients  treated  for  PTC  between  1985  and  2000
ere  retrospectively  screened  for  BRAF  mutation.  Only
atients  with  tumours  measuring  10  mm  or  larger  were
ncluded.  Informative  data  were  available  for  46  patients  of
his  population,  who  were  operated  in  our  institution:  45
ere  treated  by  one-  or  two-stage  total  thyroidectomy  and
ne  patient  was  treated  by  lobectomy  with  isthmectomy.
his  procedure  was  completed  by  unilateral  or  bilateral  neck
issection  in  17  patients.  All  patients  were  treated  by  adju-
ant  radioiodine  therapy.
Complete  remission  was  deﬁned  by  the  following  criteria:
 normal  physical  examination;
 negative  radioiodine  whole  body  scintigraphy  after  thy-
roidectomy;
 serum  thyroglobulin  less  than  3  g/L.
Recurrence  was  deﬁned  by  the  following  criteria:
 elevated  serum  thyroglobulin;
 suspicious  ultrasound  image  with  conﬁrmation  of  the  diag-
nosis  by  ﬁne  needle  aspiration  cytology.  Thyroglobulin
assay  in  ﬁne  needle  aspiration  cytology  rinsing  ﬂuid  can
also  be  an  argument  in  favour  of  recurrence;
t
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 positive  radioiodine  whole  body  scintigraphy  (which  may
remain  negative  in  the  case  of  radioiodine  resistance).
Radioiodine-refractory  patients  (radioiodine  resistance)
ere  deﬁned  as:
 patients  with  no  radioiodine  uptake  or;
 who  progressed  during  the  months  following  radioiodine
therapy  or;
 who  presented  persistent  disease  after  a  cumulative  dose
of  600  mCi.
Written  consent  was  obtained  from  the  patents  after
nforming  them  about  use  of  part  of  their  tumour  tissue  for
esearch  purposes.
dentiﬁcation  of  the  BRAF  mutation
arafﬁn-embedded  tumour  blocks  from  all  patients,  stored
n  our  institution’s  pathology  laboratory,  were  reviewed.
ive  m  sections  were  stained  with  haemalun-eosin  to
ocalize  the  most  representative  tumour  zone.  Ten  m  sec-
ions  were  performed  in  this  zone  for  tumour  genomic  DNA
xtraction.  DNA  was  isolated  after  protease  digestion  of  the
umour  and  DNA  binding  onto  a ﬁbreglass  ﬁlter.  Exon  15  was
mpliﬁed  by  PCR  using  a  speciﬁc  primer  pair:
Sense  primer:  5’-TTCCTTTACTTACTACACCTCAGATATAT-
TCTT-3’
Antisense  primer:  5’-CCAGACAACTGTTCAAACTGATGG-
’
After  agar  gel  migration,  the  PCR  product  was  puri-
ed  and  submitted  to  primer  extension.  This  technique
s  based  on  the  use  of  ﬂuorescently  labelled  dideoxynu-
leotide  triphosphate  (ddNTP).  After  PCR  and  hybridization
f  the  PCR  product  with  an  oligonucleotide  speciﬁc  for  the
’  ﬂanking  sequence  of  the  polymorphism  to  be  detected,
 DNA  polymerase  was  used  to  incorporate  the  comple-
entary  ddNTP  of  the  potentially  mutant  nucleotide.  The
uorescent  ddNTP  was  detected  by  an  ABI  3130xl  automatic
equencer  (Applied  Biosystems).  SNaPshot  analysis  demon-
trated  mutation  of  nucleotide  1799,  which  represents  90%
f  all  known  BRAF  mutations.
linical  data
o  allow  comparative  statistical  analysis,  the  main  clini-
al  data  for  each  patient  were  collected:  age  at  diagnosis,
ender,  multifocal  tumour,  extrathyroid  extension,  tumour
tage  (TNM),  recurrence.
tatistical  analysis
ata  are  expressed  as  mean  ±  standard  deviation  and  per-
entage.  The  association  between  BRAF  mutation  and
ender,  tumour  size,  extrathyroid  extension,  multifocal
umour,  presence  of  cervical  lymph  node  metastasis  and
umour  stage  was  evaluated  by  Fisher’s  exact  test.  A  Mann-
hitney  test  was  used  to  compare  the  presence  of  BRAF
utation  and  age.  A  value  of  P  <  0.05  was  considered  to  be
tatistically  signiﬁcant.
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Results
Population
Five  patients  were  lost  to  follow-up  and  DNA  could  not  be
used  for  BRAF  mutation  screening  for  two  patients.
The  mean  age  of  the  patients  included  in  the  study  was
43.2  (±  15.1)  years  and  the  mean  tumour  diameter  was  30.6
(±  15.4)  mm.  Epidemiological  and  clinicopathological  char-
acteristics  of  the  two  subgroups  are  shown  in  Table  1.
Post-treatment  follow-up  was  comparable  in  the  two
subgroups  (10  years  in  the  mutant  BRAF  subgroup  versus
10.25  years  in  the  wild-type  BRAF  subgroup).
Laboratory  study
The  T1799A  mutation  of  the  BRAF  gene  was  demonstrated  in
43.5%  of  the  PTC  studied.  Patients  were  classiﬁed  into  two
subgroups:  a  mutant  BRAF  subgroup  and  a  wild-type  BRAF
subgroup.
Statistical  analysis
The  only  statistically  signiﬁcant  difference  between  the  two
subgroups  was  a  greater  number  of  patients  with  clinical  and
histological  lymph  node  metastasis  in  the  wild-type  BRAF
subgroup  (15%/54%,  p  =  0.03).
Table  2  shows  the  correlation  between  BRAF  mutation
and  various  clinicopathological  characteristics  of  PTC.
No  signiﬁcant  correlation  was  demonstrated  between
BRAF  mutation  and  any  of  the  other  clinicopathological
criteria  studied.  At  the  end  of  the  study,  two  patients  had
died  from  their  PTC,  one  in  each  of  the  two  subgroups.  Sur-
vival  curves  for  the  two  subgroups  were  identical,  but  the
small  number  of  tumour  events  did  not  allow  any  statistically
signiﬁcant  |sions.
Mean  follow-up  after  surgery  was  10.1  (±  6.5)  years.
Eleven  patients  developed  recurrence  after  a  mean  postop-
erative  interval  of  3.5  (±  3.4)  years.  Table  3  demonstrates
the  relationship  between  recurrence  rate  and  certain  pro-
gnostic  factors.
BRAF  mutation  was  not  correlated  with  an  increased  risk
of  tumour  recurrence.
Three  patients  with  recurrence  harboured  a  BRAF  muta-
tion  in  their  primary  tumour.  Patients  with  BRAF  mutation
presented  more  extensive  recurrence  requiring  more  aggres-
sive  treatment.  For  2  out  of  3  mutant  BRAF  patients  versus
3  out  of  8  wild-type  BRAF  patients,  the  clinical  course
was  marked  by  multiple  local  recurrences  requiring  at  least
repeat  surgery  and/or  external  beam  radiotherapy.
One  patient  of  the  mutant  BRAF  subgroup  (33%)  versus
one  patient  of  the  wild-type  BRAF  subgroup  (13%)  presented
radioiodine  resistance  at  sites  of  tumour  recurrence.  The
differences  between  the  two  subgroups  were  not  signiﬁcant.
DiscussionPatients  of  the  two  subgroups  (mutant  BRAF  and  wild-type
BRAF)  were  comparable  and  corresponded  to  the  popula-
tions  reported  in  the  literature  concerning  differentiated
p
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hyroid  cancer.  Despite  the  generally  favourable  progno-
is  of  PTC  after  initial  treatment,  20  to  30%  of  patients
ubsequently  relapse  [3—5].  These  patients  often  require
ore  aggressive  complementary  management  that  does  not
lways  achieve  cure.
Many  prognostic  factors  have  been  proposed  to  rapidly
dentify  this  high-risk  population  and  consequently  limit  the
orbidity  and  mortality  related  to  PTC.  Advanced  age,  male
ender,  large  tumour  size,  extrathyroid  extension,  multifo-
al  tumour,  lymph  node  and/or  distant  metastasis  have  been
dentiﬁed  as  risk  factors  for  poor  prognosis  and  recurrence
6,7].
A  molecular  marker  such  as  BRAF, that  can  be  easily
etected  on  preoperative  ﬁne-needle  aspiration  cytology,
ould  allow  evaluation  of  the  risk  of  recurrence  at  the  time
f  diagnosis,  and  appropriate  adjustment  of  ﬁrst-line  treat-
ent  as  well  as  the  modalities  of  post-treatment  follow-up.
BRAF  mutation  is  detected  in  38  to  83%  of  PTC  with  a
ean  of  49%  and  plays  a  central  role  in  initiation  of  PTC  by
n  early  action  on  carcinogenesis.  A  similar  BRAF  mutation
ate  was  observed  in  the  present  series  (44%).
No  statistically  signiﬁcant  correlation  was  observed  in
his  study  between  the  presence  of  a  BRAF  mutation  and
umour  aggressiveness.  Patients  with  BRAF  mutation  never-
heless  appeared  to  have  a  slightly  higher  recurrence  rate
nd  recurrences  tended  to  be  more  aggressive  and  more
xtensive  in  this  subgroup.  In  contrast,  lymph  node  metas-
ases  were  more  frequent  among  patients  of  the  wild-type
RAF  subgroup.  Radioiodine  sensitivity  also  did  not  appear
o  be  signiﬁcantly  inﬂuenced  by  BRAF  mutation,  but  a  ten-
ency  towards  a  certain  degree  of  radioiodine  resistance
as  observed.  A limitation  of  this  study  was  the  small  sam-
le  size,  which  may  have  reduced  the  power  of  statistical
ests.
Some  studies  [8,9]  have  shown  that  BRAF  muta-
ion  is  associated  with  advanced  age  and  extracapsular
umour  extension.  According  to  Lupi  et  al.  [10],  BRAF
utation  is  correlated  with  extracapsular  tumour  exten-
ion,  lymph  node  metastases  and  advanced  T  stage.  In
 retrospective  series  of  219  patients,  Xing  et  al.  [11]
eported  a  signiﬁcant  correlation  with  extracapsular  tumour
xtension,  lymph  node  metastasis,  and  advanced  tumour
tage.
The  results  of  this  study  conﬁrm  those  of  larger  pub-
ished  series  [12,13].  Ito  et  al.  [13],  based  on  a  series  of
31  patients  with  a  mean  follow-up  of  83  months,  did  not
eveal  any  signiﬁcant  relationship  between  presence  of  BRAF
utation  and  age,  gender,  extrathyroid  extension,  lymph
ode  and  distant  metastases,  and  tumour  stage.
The  discordant  results  of  these  studies  have  been  dis-
ussed  in  several  meta-analyses.  The  review  of  the  literature
ublished  by  Lee  et  al.  [14],  evaluating  12  studies  including
 total  of  1168  patients,  reported  a  signiﬁcant  correlation
etween  BRAF  mutation  and  the  histological  subtype  of
TC,  extrathyroid  extension  and  advanced  tumour  stage.  In
ontrast,  no  signiﬁcant  correlation  was  observed  with  age,
ender,  tumour  size  and  the  ethnic  group.  Kim  et  al.  [15]
onﬁrmed  the  negative  impact  of  BRAF  mutation  on  the
rognosis  of  PTC.
These  discordant  results  concerning  the  prognostic  sig-
iﬁcance  of  BRAF  mutation  could  be  due  to  the  inclusion
f  various  histological  subtypes  of  PTC,  epidemiological
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Table  1  Characteristics  of  the  two  subgroups  of  the  study.
Mutant  BRAF  subgroup  Wild-type  BRAF  subgroup
Total  number  of  patients  20  26
Age at  diagnosis  (years,  mean)  45.8  41.2
Tumour size  (mm,  mean)  30.7  30.8
Gender (male/female)  2/18  9/17
Multifocal  tumour  (yes)  3  4
Extrathyroid  extension  (yes)  7  7
Cervical lymph  node  metastasis 3  14
Tumour recurrence  (yes) 3/11  8/11
Stage (number  of  patients)
pT1  6  8
pT2 5  10
pT3 9  5
f
t
T
tpT4 0  actors,  insufﬁcient  follow-up,  insufﬁcient  sample  sizes  or
he  use  of  different  methods  to  detect  BRAF  mutations.
hese  contradictory  results  could  also  be  explained  by
he  duration  of  the  disease  prior  to  initiation  of  treat-
m
s
m
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Table  2  BRAF  status  and  clinicopathological  characteristics  of  th
Total  BRAF  V600
Gender
Male  11  2  
Female 35  18  
Age at  diagnosis  (years),  mean  43.2  (±  15.1)  45.8  
Age <  45  years  20  10  
Age <  45  years  26  10  
Tumour size  (mm)
< 2  cm  11  5  
≥ 2  cm  35  15  
Extrathyroid  extension
Yes  14  7  
No 32  13  
Multifocal  nature
Yes  7  3  
No 39  17  
Cervical lymph  node  metastasis
Yes  17  3  
No 29
Stage
pT1 14  6  
pT2 15  5  
pT3 14  9  
pT4 3  0  
NS: not signiﬁcant; IC: inverse correlation.3ent,  which  differs  for  each  patient  included  in  the  various
tudies.  BRAF  mutation  is  frequently  detected  in  papillary
icrocarcinomas  [16—18]. These  tumours  have  an  excellent
rognosis  regardless  of  BRAF  status,  while  a  more  marked
e  46  patients  of  the  series.
E  mutation  (+)  BRAF  V600E  mutation  (−)  P  value
9  0.05  (NS)
17
41.2  0.18  (NS)
10  0.31  (NS)
16
6  0.57  (NS)
20
7  0.39  (NS)
19
4  0.65  (NS)
22
14  0.03  (IC)
8  0.17  (NS)
10
5
3
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Table  3  Association  between  clinicopathological  factors  and  recurrence  rate.
Sample  size  Recurrence  rate  (%)  P  value
Age  at  diagnosis
<  45  years  26  30.8  0.18  (NS)
≥ 45  years  20  15
Gender
Male 11  27.3  0.53  (NS)
Female 35  22.9
Extrathyroid  extension
Yes 14  35.7 0.19  (NS)
No 32  18.8
Multifocal  nature
Yes  7  28.6  0.54  (NS)
No 39  23.1
pT stage
T1  14  14.3  0.03
T2 15  26.7
T3 14  14.3
T4 3  0
BRAF status
Wild-type  26  72.7  0.19  (NS)
Mutant 20  27.3
•
•
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tNS: not signiﬁcant.
difference  in  prognosis  is  observed  between  more  advanced
PTC  according  to  the  presence  or  absence  of  BRAF  mutation.
This  heterogeneity  can  affect  the  probability  of  demonstrat-
ing  correlations  between  BRAF  mutation  and  prognosis  of
PTC.
BRAF  mutation  occurs  early  in  the  course  of  PTC  carcino-
genesis,  but  does  not  appear  to  be  sufﬁcient  to  confer  a
more  aggressive  phenotype.  BRAF  mutation  could  be  con-
sidered  to  predispose  tumour  cells  to  the  development  of
other  oncogenic  events,  leading  to  a  certain  degree  of  loss
of  differentiation  and  a  poorer  prognosis.
BRAF  and  tumour  recurrence
The  individual  risk  of  tumour  recurrence  is  evaluated  by  tak-
ing  into  account  the  patient’s  age  at  the  time  of  diagnosis,
the  histological  subtype  of  PTC,  the  extent  of  tumour  inva-
sion  and  the  extent  of  surgical  resection.  The  disadvantage
of  this  approach  is  that  it  cannot  be  applied  preoperatively.
Very  few  studies  have  analysed  the  correlation  between
BRAF  mutation  and  the  outcome  of  patients  with  PTC  with
long-term  postoperative  follow-up.
In  this  series,  with  a  median  follow-up  of  more  than
10  years:
•  the  presence  of  BRAF  mutation  in  the  primary  tumour  was
not  associated  with  an  increased  risk  of  recurrence.  How-
ever,  the  survival  curves  of  the  two  subgroups  could  not
be  compared  due  to  the  small  sample  size  of  this  study;
•  patients  with  BRAF  mutation  presented  more  extensive
recurrence,  requiring  more  aggressive  treatments  com-
prising  at  least  repeat  surgery  and/or  external  beam
r
n
m
sradiotherapy  compared  to  the  wild-type  BRAF  subgroup,
but  the  difference  was  not  statistically  signiﬁcant;
 the  estimated  recurrence  rate  was  24%  with  no  signiﬁcant
difference  between  the  two  subgroups;
 98%  of  patients  underwent  total  thyroidectomy,  all
received  at  least  one  dose  of  radioiodine  and  neck
dissection  was  performed  during  the  initial  surgical  man-
agement  in  37%  of  cases.  These  results  could  be  explained
by  more  extensive  initial  surgical  resection  and  adjuvant
radioiodine  therapy  that  limit  local  recurrence.
Elisei  et  al.  [19]  compared  the  survival  curves  of  patients
xpressing  wild-type  BRAF  and  those  with  BRAF  mutation
ith  a  follow-up  of  15  years.  Tumour  recurrence  and  cancer-
peciﬁc  mortality  rates  were  higher  for  BRAF  mutation
atients.
The  results  of  the  present  study  are  similar  to  those
eported  by  Can˜adas  Garre  et  al.  [20],  who  concluded  on  the
bsence  of  any  signiﬁcant  correlation  between  BRAF  muta-
ion  and  tumour  recurrence,  progressive  disease  and  the  use
f  aggressive  adjuvant  therapy.
The  quality  of  the  initial  resection  and  the  use  of  adju-
ant  radioiodine  therapy  could  compensate  for  the  negative
ffect  of  BRAF  mutation  on  the  course  of  PTC  [6,21].
In  this  series,  the  lymph  node  metastasis  rate  was  higher
mong  patients  in  the  wild-type  BRAF  subgroup.  This  sta-
istically  signiﬁcant  difference  is  in  contradiction  with  the
esults  of  the  meta-analysis  by  Lee  [14], in  which  the  lymph
ode  metastasis  rate  was  non-signiﬁcantly  higher  in  the
utant  BRAF  subgroup.  This  difference  could  be  due  to  the
mall  sample  size  of  our  study,  as  well  as  ethnic  difference,
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s  one  half  of  the  patients  included  in  Lee’s  meta-analysis
ere  of  Asian  origin.
RAF  and  radioiodine  resistance
n  association  between  BRAF  mutation  and  the  expres-
ion  of  certain  genes  involved  in  radioiodine  metabolism
as  been  proposed  as  a  possible  explanation  for  treatment
ailures  and  recurrence  of  PTC.  BRAF  mutation  appears
o  be  associated  with  radioiodine  resistance,  responsible
or  a  higher  recurrence  rate.  Abnormalities  of  tumour
odine  metabolism  appear  to  be  related  to  decreased
xpression  of  the  sodium-iodine  symporter  (NIS)  and  thy-
operoxidase.  Some  teams  [22—24]  have  shown  that  BRAF
utation  alters  the  transcription  of  the  gene  encoding  NIS
nd  decreases  its  membrane  expression,  while  other  teams
25]  failed  to  demonstrate  any  link  between  BRAF  mutation
nd  NIS  expression,  suggesting  that  decreased  NIS  expres-
ion  is  not  the  only  mechanism  responsible  for  radioiodine
esistance.
In  this  study,  no  signiﬁcant  difference  in  radioiodine
ensitivity  was  observed  between  the  mutant  BRAF  and  wild-
ype  BRAF  subgroups,  probably  because  of  the  small  sample
ize.
onclusion
his  study  analysed  the  correlations  between  BRAF  muta-
ion  and  clinicopathological  characteristics  as  well  as  the
ong-term  prognosis  of  PTC.  No  signiﬁcant  correlation  was
bserved  between  BRAF  mutation  and  the  various  clini-
opathological  factors  known  to  be  associated  with  poor
rognosis  of  PTC.  BRAF  mutation  was  also  not  correlated
ith  an  increased  tumour  recurrence  rate  after  ﬁrst-line
reatment  or  with  radioiodine  sensitivity.  A  multicentre
tudy  based  on  a  larger  sample  size  with  long-term  follow-
p  should  be  conducted  to  clarify  the  role  of  BRAF  mutation
n  PTC  tumour  aggressiveness.
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